Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

0.8600 -0.0500 (-5.49%)

Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Life Science Virtual Investor Forum Agenda Announced for September 18th

September 16, 2025

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

September 16, 2025

Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

September 10, 2025

Via ACCESS Newswire

Dermata to Present on BioPub on January 31, 2025

January 29, 2025

Via ACCESS Newswire

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

December 16, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 03, 2025

Via Benzinga

Dermata Posts Narrower Loss in Q2 ↗

August 13, 2025

Via The Motley Fool

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 13, 2025

Via ACCESS Newswire

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

July 08, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 07, 2025

Via Benzinga

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

December 10, 2024

Via ACCESSWIRE

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

December 03, 2024

Via ACCESSWIRE

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025

Via ACCESS Newswire

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

April 15, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 28, 2025

Via Benzinga

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

March 28, 2025

Via Benzinga

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 13, 2024

Via ACCESSWIRE

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets' ↗

March 28, 2025

U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower.

Via Benzinga

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

March 27, 2025

Via ACCESS Newswire

Which stocks are gapping on Thursday? ↗

March 27, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results ↗

March 27, 2025

Via Benzinga

Top movers in Thursday's pre-market session ↗

March 27, 2025

Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne ↗

March 27, 2025

Dermata's Xyngari showed significant acne improvement in Phase 3 results. A second pivotal trial is set for the second half of 2025.

Via Benzinga

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall ↗

March 27, 2025

Via Benzinga

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

March 17, 2025

Via ACCESS Newswire

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

February 25, 2025

Via ACCESS Newswire

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

January 22, 2025

Via ACCESS Newswire

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

January 21, 2025

Via ACCESS Newswire

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

November 15, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Life Sciences Investor Forum Agenda Announced for November 14th

November 12, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.